Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC022 adaptive combination therapy trial in children and young adults with diffuse midline glioma
NL-OMON60145Phase 2Suspended
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dordaviprone in diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG) (6 cohorts), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Progression-free survival at 6 months and Overall survival at 7 months. Started Oct 2022; status: suspended.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NL-OMON60145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60145.